Elevance Health (ELV)
Elevance Health on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as hospital & medical service plans.
5.1M
Short interest
settlement 2026-10-15
4.0
Days to cover
+0.1 days vs prior
46.0%
Short share of volume
2026-10-28
2,120
Fails to deliver
settlement 2026-09-21
Wed 27 Jan
Next earnings
estimated date
-$4.7M
Insider flow, 90 days
0 buys, 13 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ELV is 5,137,559 shares, down 198,064 shares over the last month. Over the last 48 readings it ranged from 2,199,507 shares (30 May 2025) to 6,604,471 shares (29 May 2026). At the reported average volume of 1.3M shares a day that is 4.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/elv" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,137,559 | +5.8% | 1,285,082 | 4.00 |
| 2026-09-30 | 4,854,598 | -9.0% | 1,236,911 | 3.92 |
| 2026-09-15 | 5,335,623 | -2.7% | 1,267,937 | 4.21 |
| 2026-08-31 | 5,485,788 | +1.5% | 836,685 | 6.56 |
| 2026-08-14 | 5,405,640 | -3.2% | 952,831 | 5.67 |
| 2026-07-31 | 5,586,082 | -7.3% | 1,422,031 | 3.93 |
| 2026-07-15 | 6,025,314 | +0.3% | 1,709,546 | 3.52 |
| 2026-06-30 | 6,009,556 | -4.3% | 1,835,606 | 3.27 |
| 2026-06-15 | 6,281,369 | -4.9% | 1,785,160 | 3.52 |
| 2026-05-29 | 6,604,471 | +8.3% | 1,520,194 | 4.34 |
| 2026-05-15 | 6,101,072 | +18.3% | 1,658,684 | 3.68 |
| 2026-04-30 | 5,158,417 | +16.8% | 2,032,973 | 2.54 |
| 2026-04-15 | 4,417,945 | +11.3% | 1,490,828 | 2.96 |
| 2026-03-31 | 3,970,576 | +8.2% | 1,622,036 | 2.45 |
| 2026-03-13 | 3,669,028 | -13.2% | 3,161,016 | 1.16 |
| 2026-02-27 | 4,227,962 | -9.1% | 1,581,890 | 2.67 |
| 2026-02-13 | 4,649,830 | +29.3% | 1,722,452 | 2.70 |
| 2026-01-30 | 3,595,465 | -2.5% | 2,295,153 | 1.57 |
| 2026-01-15 | 3,685,633 | -10.1% | 1,224,916 | 3.01 |
| 2025-12-31 | 4,098,765 | -14.0% | 1,393,947 | 2.94 |
| 2025-12-15 | 4,764,383 | +22.7% | 1,706,213 | 2.79 |
| 2025-11-28 | 3,883,536 | -3.9% | 1,489,461 | 2.61 |
| 2025-11-14 | 4,041,947 | +16.2% | 1,537,722 | 2.63 |
| 2025-10-31 | 3,479,088 | +27.4% | 1,907,047 | 1.82 |
| 2025-10-15 | 2,731,969 | -14.7% | 1,815,700 | 1.50 |
| 2025-09-30 | 3,202,284 | -12.9% | 1,920,532 | 1.67 |
| 2025-09-15 | 3,677,507 | +36.2% | 2,104,185 | 1.75 |
| 2025-08-29 | 2,700,482 | -14.5% | 2,069,890 | 1.30 |
| 2025-08-15 | 3,156,964 | +11.1% | 2,466,106 | 1.28 |
| 2025-07-31 | 2,840,716 | +4.5% | 3,961,129 | 1.00 |
| 2025-07-15 | 2,719,541 | +7.1% | 2,152,272 | 1.26 |
| 2025-06-30 | 2,539,048 | +1.4% | 1,568,159 | 1.62 |
| 2025-06-13 | 2,503,358 | +13.8% | 1,602,999 | 1.56 |
| 2025-05-30 | 2,199,507 | -15.6% | 2,000,055 | 1.10 |
| 2025-05-15 | 2,606,814 | -2.7% | 1,644,255 | 1.59 |
| 2025-04-30 | 2,677,922 | -12.4% | 1,777,794 | 1.51 |
| 2025-04-15 | 3,058,842 | +11.4% | 2,115,716 | 1.45 |
| 2025-03-31 | 2,745,373 | +8.8% | 1,512,474 | 1.82 |
| 2025-03-14 | 2,523,417 | +1.8% | 1,758,857 | 1.43 |
| 2025-02-28 | 2,479,317 | -23.7% | 1,593,254 | 1.56 |
| 2025-02-14 | 3,249,711 | +15.5% | 1,307,845 | 2.48 |
| 2025-01-31 | 2,813,248 | -3.5% | 2,018,014 | 1.39 |
| 2025-01-15 | 2,914,476 | -19.6% | 1,564,762 | 1.86 |
| 2024-12-31 | 3,626,261 | +5.2% | 1,831,518 | 1.98 |
| 2024-12-13 | 3,446,396 | +22.3% | 2,050,105 | 1.68 |
| 2024-11-29 | 2,817,457 | -10.1% | 1,695,198 | 1.66 |
| 2024-11-15 | 3,132,470 | +10.1% | 2,093,892 | 1.50 |
| 2024-10-31 | 2,846,378 | +6.7% | 2,594,835 | 1.10 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of ELV volume is 46.0%, down 0.2 points over the last five sessions. Over the last 30 readings it ranged from 30.1% (27 October 2026) to 75.7% (5 October 2026). The latest reading is 4.8 points below the 30-session average of 50.8%, on 485K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 223K | 485K | 46.0% | 357 |
| 2026-10-27 | 187K | 620K | 30.1% | 43 |
| 2026-10-26 | 228K | 414K | 55.0% | 421 |
| 2026-10-23 | 269K | 524K | 51.3% | 654 |
| 2026-10-22 | 328K | 532K | 61.6% | 2,512 |
| 2026-10-21 | 497K | 1.1M | 46.3% | 2,268 |
| 2026-10-20 | 258K | 576K | 44.8% | 4,496 |
| 2026-10-19 | 176K | 336K | 52.6% | 3,289 |
| 2026-10-16 | 209K | 452K | 46.2% | 1,531 |
| 2026-10-15 | 227K | 628K | 36.1% | 1,484 |
| 2026-10-14 | 497K | 820K | 60.7% | 195 |
| 2026-10-13 | 397K | 601K | 66.2% | 1,214 |
| 2026-10-12 | 196K | 324K | 60.5% | 3,136 |
| 2026-10-09 | 398K | 1.0M | 38.7% | 1,397 |
| 2026-10-08 | 160K | 270K | 59.2% | 46 |
| 2026-10-07 | 192K | 333K | 57.7% | 799 |
| 2026-10-06 | 156K | 268K | 58.1% | 58 |
| 2026-10-05 | 187K | 247K | 75.7% | 198 |
| 2026-10-02 | 143K | 326K | 43.8% | 0 |
| 2026-10-01 | 219K | 397K | 55.2% | 146 |
| 2026-09-30 | 215K | 442K | 48.5% | 58 |
| 2026-09-29 | 159K | 306K | 51.9% | 145 |
| 2026-09-28 | 226K | 458K | 49.4% | 22 |
| 2026-09-25 | 215K | 474K | 45.4% | 9 |
| 2026-09-24 | 205K | 458K | 44.7% | 1,374 |
| 2026-09-23 | 176K | 475K | 37.1% | 494 |
| 2026-09-22 | 182K | 397K | 45.9% | 0 |
| 2026-09-21 | 178K | 284K | 62.6% | 15 |
| 2026-09-18 | 154K | 304K | 50.6% | 36 |
| 2026-09-17 | 219K | 533K | 41.1% | 84 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 21 September 2026, the fails-to-deliver balance in ELV is 2,120 shares, up 2,116 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (7 April 2026) to 67,056 shares (9 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-21 | 2,120 | $410.95 | $871K |
| 2026-09-14 | 4 | $418.72 | $2K |
| 2026-09-02 | 570 | $403.04 | $230K |
| 2026-08-24 | 1,100 | $400.54 | $441K |
| 2026-08-04 | 1,635 | $382.77 | $626K |
| 2026-08-03 | 5,331 | $375.84 | $2.0M |
| 2026-07-02 | 23,410 | $416.19 | $9.7M |
| 2026-06-30 | 4,812 | $388.03 | $1.9M |
| 2026-06-25 | 6 | $384.00 | $2K |
| 2026-06-23 | 21,398 | $394.82 | $8.4M |
| 2026-06-22 | 25,439 | $388.50 | $9.9M |
| 2026-06-16 | 6 | $401.89 | $2K |
| 2026-06-10 | 1,099 | $424.43 | $466K |
| 2026-05-29 | 2,953 | $392.75 | $1.2M |
| 2026-05-26 | 167 | $394.69 | $66K |
| 2026-05-21 | 18,728 | $396.21 | $7.4M |
| 2026-05-20 | 1 | $402.27 | $402 |
| 2026-05-18 | 1,356 | $392.68 | $532K |
| 2026-05-14 | 76 | $399.64 | $30K |
| 2026-04-15 | 3 | $313.35 | $940 |
| 2026-04-07 | 1 | $302.61 | $303 |
| 2026-04-06 | 101 | $300.74 | $30K |
| 2026-04-01 | 127 | $292.75 | $37K |
| 2026-03-31 | 384 | $284.79 | $109K |
| 2026-03-26 | 12,713 | $296.09 | $3.8M |
| 2026-03-25 | 31 | $290.33 | $9K |
| 2026-03-19 | 24 | $294.95 | $7K |
| 2026-03-10 | 135 | $280.74 | $38K |
| 2026-03-09 | 67,056 | $289.64 | $19.4M |
| 2026-03-02 | 21 | $320.00 | $7K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ELV reported 13 open-market sells worth $4.7M in the last 90 days and no open-market buys. Latest filing: Kaye Mark (EVP & CFO) on 2026-10-22.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 273 | $447.19 | $122K | 20K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 827 | $446.05 | $369K | 20K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 160 | $444.85 | $71K | 21K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 440 | $443.81 | $195K | 21K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 480 | $442.61 | $212K | 22K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 2K | $441.34 | $1.0M | 22K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 2K | $440.44 | $758K | 24K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 1K | $439.25 | $510K | 26K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 240 | $438.22 | $105K | 27K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 560 | $437.07 | $245K | 28K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 2K | $436.20 | $724K | 28K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 321 | $435.25 | $140K | 30K |
| 2026-10-22 | Kaye Mark | EVP & CFO | Sell | 400 | $434.00 | $174K | 30K |
| 2026-10-02 | Kaye Mark | EVP & CFO | Grant | 3K | $0.00 | $0 | 31K |
| 2026-10-02 | Kaye Mark | EVP & CFO | Tax withholding | 4K | $386.43 | $1.6M | 28K |
| 2026-09-03 | Wessling Erin M | EVP & Chief Legal Officer | Tax withholding | 255 | $414.78 | $106K | 7K |
| 2026-09-02 | Wessling Erin M | EVP & Chief Legal Officer | Tax withholding | 94 | $405.84 | $38K | 7K |
| 2026-09-02 | Craig Ryan R | EVP & Chief HR Officer | Tax withholding | 144 | $405.84 | $58K | 7K |
| 2026-07-17 | PERU RAMIRO G | Director | Buy | 1K | $366.05 | $366K | 11K |
| 2026-07-17 | BOUDREAUX GAIL | President and CEO | Buy | 2K | $368.25 | $753K | 172K |
| 2026-07-17 | BOUDREAUX GAIL | President and CEO | Buy | 680 | $366.41 | $249K | 170K |
| 2026-06-12 | Penczek Ronald W | CAO & Controller | Sell | 369 | $403.16 | $149K | 4K |
| 2026-06-11 | Dixon Robert L JR | Director | Sell | 151 | $401.77 | $61K | 11K |
| 2026-05-19 | Penczek Ronald W | CAO & Controller | Sell | 2K | $403.13 | $617K | 4K |
| 2026-05-19 | Penczek Ronald W | CAO & Controller | Exercise or conversion | 877 | $311.48 | $273K | 6K |
| 2026-05-19 | Penczek Ronald W | CAO & Controller | Exercise or conversion | 654 | $271.27 | $177K | 5K |
| 2026-05-13 | Jallal Bahija | Director | Grant | 563 | $0.00 | $0 | 5K |
| 2026-05-13 | Neri Antonio F | Director | Grant | 563 | $0.00 | $0 | 5K |
| 2026-05-13 | STRABLE-SOETHOUT DEANNA D | Director | Grant | 563 | $0.00 | $0 | 2K |
| 2026-05-13 | SCHULMAN AMY W | Director | Grant | 563 | $0.00 | $0 | 781 |
| 2026-05-13 | Schneider Ryan M. | Director | Grant | 563 | $0.00 | $0 | 7K |
| 2026-05-13 | PERU RAMIRO G | Director | Grant | 563 | $0.00 | $0 | 10K |
| 2026-05-13 | HAY LEWIS III | Director | Grant | 563 | $0.00 | $0 | 12K |
| 2026-05-13 | Dixon Robert L JR | Director | Grant | 563 | $0.00 | $0 | 11K |
| 2026-05-13 | DeVore Susan D. | Director | Grant | 563 | $0.00 | $0 | 4K |
| 2026-05-13 | COLLIS STEVEN H | Director | Grant | 563 | $0.00 | $0 | 4K |
| 2026-03-12 | SCHULMAN AMY W | Director | Sell | 26 | $287.50 | $7K | 218 |
| 2026-03-06 | Kendrick Charles Morgan JR | EVP & President, Commercial | Sell | 3K | $284.92 | $911K | 12K |
| 2026-03-05 | COLLIS STEVEN H | Director | Buy | 3K | $289.84 | $870K | 4K |
| 2026-03-03 | Wessling Erin M | EVP & Chief Legal Officer | Tax withholding | 417 | $284.03 | $118K | 8K |
| 2026-03-03 | Kendrick Charles Morgan JR | EVP & President, Commercial | Tax withholding | 467 | $284.03 | $133K | 15K |
| 2026-03-03 | Kaye Mark | EVP & CFO | Tax withholding | 353 | $284.03 | $100K | 32K |
| 2026-03-03 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | Tax withholding | 496 | $284.03 | $141K | 39K |
| 2026-03-03 | LAVU RATNAKAR | EVP & Chief Digital Info Ofr | Tax withholding | 222 | $284.03 | $63K | 16K |
| 2026-03-03 | Penczek Ronald W | CAO & Controller | Tax withholding | 37 | $284.03 | $11K | 4K |
| 2026-03-03 | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | Tax withholding | 446 | $284.03 | $127K | 27K |
| 2026-03-03 | Craig Ryan R | EVP & Chief HR Officer | Tax withholding | 309 | $284.03 | $88K | 7K |
| 2026-03-03 | BOUDREAUX GAIL | President and CEO | Tax withholding | 2K | $284.03 | $493K | 169K |
| 2026-03-02 | Wessling Erin M | EVP & Chief Legal Officer | Grant | 3K | $0.00 | $0 | 8K |
| 2026-03-02 | Kendrick Charles Morgan JR | EVP & President, Commercial | Grant | 3K | $0.00 | $0 | 15K |
| 2026-03-02 | Kendrick Charles Morgan JR | EVP & President, Commercial | Grant | 4K | $0.00 | $0 | 13K |
| 2026-03-02 | Kendrick Charles Morgan JR | EVP & President, Commercial | Tax withholding | 1K | $294.07 | $356K | 9K |
| 2026-03-02 | Kaye Mark | EVP & CFO | Grant | 10K | $0.00 | $0 | 32K |
| 2026-03-02 | Kaye Mark | EVP & CFO | Grant | 6K | $0.00 | $0 | 22K |
| 2026-03-02 | Kaye Mark | EVP & CFO | Tax withholding | 271 | $294.07 | $80K | 16K |
| 2026-03-02 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | Grant | 3K | $0.00 | $0 | 39K |
| 2026-03-02 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | Grant | 6K | $0.00 | $0 | 36K |
| 2026-03-02 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | Tax withholding | 1K | $294.07 | $418K | 31K |
| 2026-03-02 | LAVU RATNAKAR | EVP & Chief Digital Info Ofr | Grant | 7K | $0.00 | $0 | 16K |
| 2026-03-02 | LAVU RATNAKAR | EVP & Chief Digital Info Ofr | Grant | 5K | $0.00 | $0 | 10K |
| 2026-03-02 | LAVU RATNAKAR | EVP & Chief Digital Info Ofr | Tax withholding | 315 | $294.07 | $93K | 4K |
| 2026-03-02 | Penczek Ronald W | CAO & Controller | Grant | 266 | $0.00 | $0 | 4K |
| 2026-03-02 | Penczek Ronald W | CAO & Controller | Grant | 2K | $0.00 | $0 | 4K |
| 2026-03-02 | Penczek Ronald W | CAO & Controller | Grant | 426 | $0.00 | $0 | 2K |
| 2026-03-02 | Penczek Ronald W | CAO & Controller | Tax withholding | 131 | $294.07 | $39K | 2K |
| 2026-03-02 | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | Grant | 3K | $0.00 | $0 | 28K |
| 2026-03-02 | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | Tax withholding | 1K | $294.07 | $353K | 25K |
| 2026-03-02 | Craig Ryan R | EVP & Chief HR Officer | Grant | 3K | $0.00 | $0 | 7K |
| 2026-03-02 | Craig Ryan R | EVP & Chief HR Officer | Tax withholding | 25 | $294.07 | $7K | 4K |
| 2026-03-02 | BOUDREAUX GAIL | President and CEO | Grant | 11K | $0.00 | $0 | 171K |
| 2026-03-02 | BOUDREAUX GAIL | President and CEO | Grant | 16K | $0.00 | $0 | 160K |
| 2026-03-02 | BOUDREAUX GAIL | President and CEO | Tax withholding | 7K | $294.07 | $2.0M | 144K |
| 2026-02-02 | SCHULMAN AMY W | Director | Grant | 218 | $0.00 | $0 | 218 |
| 2026-02-02 | Craig Ryan R | EVP & Chief HR Officer | Tax withholding | 279 | $341.83 | $95K | 4K |
| 2025-10-02 | Kaye Mark | EVP & CFO | Tax withholding | 3K | $340.24 | $985K | 16K |
| 2025-09-03 | Wessling Erin M | EVP & Chief Legal Officer | Tax withholding | 152 | $321.59 | $49K | 5K |
| 2025-09-02 | Wessling Erin M | EVP & Chief Legal Officer | Grant | 931 | $0.00 | $0 | 5K |
| 2025-09-02 | Craig Ryan R | EVP & Chief HR Officer | Grant | 970 | $0.00 | $0 | 5K |
| 2025-08-19 | DeVore Susan D. | Director | Buy | 1K | $312.15 | $375K | 4K |
| 2025-08-01 | COLLIS STEVEN H | Director | Grant | 639 | $0.00 | $0 | 639 |
| 2025-07-18 | BOUDREAUX GAIL | President and CEO | Buy | 1K | $287.96 | $302K | 151K |
| 2025-07-18 | BOUDREAUX GAIL | President and CEO | Buy | 5K | $287.12 | $1.5M | 150K |
| 2025-07-18 | BOUDREAUX GAIL | President and CEO | Buy | 2K | $286.07 | $668K | 145K |
| 2025-05-14 | CLARK R KERRY | Director | Grant | 601 | $0.00 | $0 | 10K |
| 2025-05-14 | DeVore Susan D. | Director | Grant | 601 | $0.00 | $0 | 2K |
| 2025-05-14 | Dixon Robert L JR | Director | Grant | 601 | $0.00 | $0 | 10K |
| 2025-05-14 | HAY LEWIS III | Director | Grant | 601 | $0.00 | $0 | 12K |
| 2025-05-14 | Jallal Bahija | Director | Grant | 601 | $0.00 | $0 | 5K |
| 2025-05-14 | Neri Antonio F | Director | Grant | 601 | $0.00 | $0 | 5K |
| 2025-05-14 | PERU RAMIRO G | Director | Grant | 601 | $0.00 | $0 | 9K |
| 2025-05-14 | Schneider Ryan M. | Director | Grant | 601 | $0.00 | $0 | 7K |
| 2025-05-14 | STRABLE-SOETHOUT DEANNA D | Director | Grant | 601 | $0.00 | $0 | 2K |
| 2025-04-24 | Kaye Mark | EVP & CFO | Sell | 5K | $424.82 | $1.9M | 19K |
| 2025-03-10 | Penczek Ronald W | CAO & Controller | Sell | 443 | $415.13 | $184K | 2K |
| 2025-03-05 | Kendrick Charles Morgan JR | EVP & President, Commercial | Sell | 4K | $396.30 | $1.4M | 10K |
| 2025-03-03 | BOUDREAUX GAIL | President and CEO | Tax withholding | 10K | $395.50 | $4.1M | 116K |
| 2025-03-03 | BOUDREAUX GAIL | President and CEO | Grant | 16K | $0.00 | $0 | 143K |
| 2025-03-03 | BOUDREAUX GAIL | President and CEO | Grant | 11K | $0.00 | $0 | 127K |
| 2025-03-03 | Kaye Mark | EVP & CFO | Grant | 4K | $0.00 | $0 | 24K |
| 2025-03-03 | Kaye Mark | EVP & CFO | Tax withholding | 270 | $395.50 | $107K | 20K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON6 Form 144 notices on file for ELV worth $7.0M at the prices reported; 1 in the last 90 days worth $4.7M. Latest: MARK B KAYE filed on 2026-10-22 to sell 10,584 shares ($4.7M) from 2026-10-22.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-22 | MARK B KAYEOfficer | 11K | $4.7M | 0.005% | 2026-10-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-07 | CLARK R KERRYDirector | 2K | $630K | 0.001% | 2026-07-07 | FIDELITY BROKERAGE SERVICES LLC |
| 2026-06-12 | RONALD WILLIAM PENCZEKOfficer | 369 | $149K | 0.000% | 2026-06-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-11 | Dixon Robert L JRDirector | 151 | $61K | 0.000% | 2026-06-11 | RBC CAPITAL MARKETS LLC |
| 2026-05-19 | RONALD WILLIAM PENCZEKOfficer | 2K | $617K | 0.001% | 2026-05-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-06 | CHARLES MORGAN KENDRICKOfficer | 3K | $911K | 0.001% | 2026-03-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of ELV in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.1% of the class (16,601,224 shares), filed 2026-04-29 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 16.6M | 7.1% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 11 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding ELV at their latest 13F. JSON8 of the 30 tracked managers held ELV at their latest 13F, $1.48B in total at quarter-end prices. Baupost Group is the largest at $493.1M (9.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Baupost Group | 2026-06-30 | 1.3M | $493.1M | 9.11% | 0 |
| Citadel Advisors | 2026-06-30 | 906K | $350.5M | 0.04% | -656K |
| Millennium Management | 2026-06-30 | 728K | $281.4M | 0.10% | -192K |
| AQR Capital Management | 2026-06-30 | 426K | $164.4M | 0.06% | +108K |
| Renaissance Technologies | 2026-06-30 | 201K | $77.9M | 0.11% | +186K |
| Two Sigma Investments | 2026-06-30 | 162K | $62.7M | 0.05% | +161K |
| D. E. Shaw & Co. | 2026-06-30 | 140K | $54.3M | 0.03% | -266K |
| Fisher Asset Management | 2026-06-30 | 2K | $623K | 0.00% | -235 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q3 FY 2026 (quarter ended 2026-09-30) Elevance Health reported revenue of $51.43B, up 1.4% from the same quarter a year earlier, and net income of $1.36B (6.27 diluted EPS). In FY 2025 it generated $4.29B of operating cash flow and spent $2.60B on buybacks and $1.53B on dividends. As of 2026-09-30, cash was $10.35B against $30.76B of debt.
- Cash
- $10.35B
- Debt
- $30.76B
- Equity
- $44.68B
- Total assets
- $127.80B
- Shares outstanding
- 216,055,891
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q3 FY 2026 | 2026-09-30 | $51.43B | $1.36B | 2.7% | 6.27 |
| Q2 FY 2026 | 2026-06-30 | $50.47B | $1.46B | 2.9% | 6.71 |
| Q1 FY 2026 | 2026-03-31 | $50.18B | $1.76B | 3.5% | 8.00 |
| Q4 FY 2025derived | 2025-12-31 | $49.75B | $547.0M | 1.1% | n/a |
| Q3 FY 2025 | 2025-09-30 | $50.71B | $1.19B | 2.3% | 5.32 |
| Q2 FY 2025 | 2025-06-30 | $49.78B | $1.74B | 3.5% | 7.72 |
| Q1 FY 2025 | 2025-03-31 | $48.89B | $2.18B | 4.5% | 9.61 |
| Q4 FY 2024derived | 2024-12-31 | $45.44B | $418.0M | 0.9% | n/a |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $199.13B | $5.66B | $4.29B | $1.12B | $2.60B | $1.53B |
| FY 2024 | 2024-12-31 | $177.01B | $5.98B | $5.81B | $1.26B | $2.90B | $1.51B |
| FY 2023 | 2023-12-31 | $171.34B | $5.99B | $8.06B | $1.30B | $2.68B | $1.40B |
| FY 2022 | 2022-12-31 | $156.59B | $5.89B | $8.40B | $1.15B | $2.32B | $1.23B |
| FY 2021 | 2021-12-31 | $138.64B | $6.16B | $8.36B | $1.09B | $1.90B | $1.10B |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-09-30; shares outstanding as of 2026-10-15 from the cover page.
What this page is
Elevance Health in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Elevance Health (ELV), SEC CIK 1156039, listed on NYSE, classified by the SEC as hospital & medical service plans. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-21.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-22.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-04-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-09-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-21.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-22.JSON and CSV
- Company record
- EDGAR filing index for CIK 1156039Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as hospital & medical service plans
Other company pages
- UALUnited Airlines Holdings
- UBERUber Technologies
- UDRUDR
- UHSUniversal Health Services
- ULUnilever
- ULTAUlta Beauty
- UMCUnited Microelectronics
- UNMUnum Group
- UNPUnion Pacific
- UPSUnited Parcel Service
- URIUnited Rentals
- USARUSA Rare Earth
- USBUS Bancorp \de\
- USFDUS Foods Holding
- USOUnited States Oil Fund
- UTHRUnited Therapeutics
Datasets
Frequently Asked Questions
How much of ELV is sold short?
5,137,559 shares were held short at the 2026-10-15 settlement, 4.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ELV's daily short volume?
On 2026-10-28, 223,236 of the 485,237 ELV shares reported to FINRA were sold short, 46.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ELV have fails to deliver?
The SEC's latest file shows 2,120 ELV shares failed to deliver at settlement 2026-09-21. Fails are reported per settlement date and published twice a month with a lag.
Are ELV insiders buying or selling?
Insiders at ELV reported 13 open-market sells worth $4.7M in the last 90 days and no open-market buys. Latest filing: Kaye Mark (EVP & CFO) on 2026-10-22.
Have ELV insiders filed to sell?
6 Form 144 notices on file for ELV worth $7.0M at the prices reported; 1 in the last 90 days worth $4.7M. Latest: MARK B KAYE filed on 2026-10-22 to sell 10,584 shares ($4.7M) from 2026-10-22.
Who owns 5% or more of ELV?
1 holder reports 5% or more of ELV in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.1% of the class (16,601,224 shares), filed 2026-04-29 for an event on 2026-03-31.
What did ELV report last quarter?
In Q3 FY 2026 (quarter ended 2026-09-30) Elevance Health reported revenue of $51.43B, up 1.4% from the same quarter a year earlier, and net income of $1.36B (6.27 diluted EPS). In FY 2025 it generated $4.29B of operating cash flow and spent $2.60B on buybacks and $1.53B on dividends. As of 2026-09-30, cash was $10.35B against $30.76B of debt.
Which tracked 13F managers own ELV?
8 of the 30 tracked 13F managers held ELV shares at their latest filing, $1.48B in all. The largest: Seth Klarman's Baupost Group (1.3M shares, $493.1M), Ken Griffin's Citadel Advisors (906K shares, $350.5M), Izzy Englander's Millennium Management (728K shares, $281.4M), Cliff Asness's AQR Capital Management (426K shares, $164.4M), Renaissance Technologies (201K shares, $77.9M), Two Sigma Investments (162K shares, $62.7M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.